Adial Pharmaceuticals Closes First $32 Million Tranche of Financing

MT Newswires Live06-16 20:44

Adial Pharmaceuticals (ADIL) said Tuesday it has closed the first $32 million tranche of its previously announced private placement of up to $64 million, including the conversion of outstanding notes assumed through its acquisition of Azora Therapeutics.

The company said the financing was led by Coastlands Capital, with participation from Kern Capital, Boxer Capital Management, Stonepine Capital Management, AuGC BioFund, as well as other institutional investors, insiders and members of management.

Adial said proceeds from the financing will support the development of its lead colon-targeted AhR program through upcoming clinical milestones and help drive long-term shareholder value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment